Sandeep R Sehdev, Nigel S B Rawson, Olexiy I Aseyev, Catriona J Buick, Marcus O Butler, Scott Edwards, Sharlene Gill, Joanna M Gotfrit, Cyrus C Hsia, Rosalyn A Juergens, Mita Manna, Joy S McCarthy, Som D Mukherjee, Stephanie L Snow, Silvana Spadafora, David J Stewart, Jason R Wentzell, Ralph P W Wong, Pawel G Zalewski
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps delay access and prevent health care providers from being able to prescribe optimal therapy. Eighteen Canadian oncology clinicians from the medicine, nursing and pharmacy professions met to develop consensus recommendations for defining reasonable government performance standards around process and timeliness to improve Canadian cancer patients' access to best care...
March 29, 2024: Current Oncology